CL2023001750A1 - Compuestos útiles para inhibir canales de sodio activados por voltaje de nav1.8 y tratar enfermedades - Google Patents
Compuestos útiles para inhibir canales de sodio activados por voltaje de nav1.8 y tratar enfermedadesInfo
- Publication number
- CL2023001750A1 CL2023001750A1 CL2023001750A CL2023001750A CL2023001750A1 CL 2023001750 A1 CL2023001750 A1 CL 2023001750A1 CL 2023001750 A CL2023001750 A CL 2023001750A CL 2023001750 A CL2023001750 A CL 2023001750A CL 2023001750 A1 CL2023001750 A1 CL 2023001750A1
- Authority
- CL
- Chile
- Prior art keywords
- voltage
- sodium channels
- inhibiting
- gated sodium
- treating diseases
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 4
- 108010056565 NAV1.8 Voltage-Gated Sodium Channel Proteins 0.000 title abstract 2
- 102000004194 NAV1.8 Voltage-Gated Sodium Channel Human genes 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 abstract 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127341P | 2020-12-18 | 2020-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001750A1 true CL2023001750A1 (es) | 2024-01-19 |
Family
ID=79025144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001750A CL2023001750A1 (es) | 2020-12-18 | 2023-06-15 | Compuestos útiles para inhibir canales de sodio activados por voltaje de nav1.8 y tratar enfermedades |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4262978A1 (enExample) |
| JP (1) | JP2024502231A (enExample) |
| KR (1) | KR20230121827A (enExample) |
| CN (1) | CN116710463A (enExample) |
| AU (1) | AU2021403606B2 (enExample) |
| CA (1) | CA3202328A1 (enExample) |
| CL (1) | CL2023001750A1 (enExample) |
| CO (1) | CO2023008049A2 (enExample) |
| IL (1) | IL303795A (enExample) |
| MX (1) | MX2023007244A (enExample) |
| PH (1) | PH12023551406A1 (enExample) |
| SA (1) | SA523441263B1 (enExample) |
| WO (1) | WO2022129283A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201604477SA (en) * | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| GB201322602D0 (en) * | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| KR102714561B1 (ko) * | 2017-05-16 | 2024-10-10 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭 |
| MA56398A (fr) * | 2019-06-27 | 2022-05-04 | Glaxosmithkline Ip Dev Ltd | Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8 |
-
2021
- 2021-12-16 MX MX2023007244A patent/MX2023007244A/es unknown
- 2021-12-16 WO PCT/EP2021/086101 patent/WO2022129283A1/en not_active Ceased
- 2021-12-16 KR KR1020237023878A patent/KR20230121827A/ko active Pending
- 2021-12-16 IL IL303795A patent/IL303795A/en unknown
- 2021-12-16 CA CA3202328A patent/CA3202328A1/en active Pending
- 2021-12-16 JP JP2023536951A patent/JP2024502231A/ja not_active Ceased
- 2021-12-16 PH PH1/2023/551406A patent/PH12023551406A1/en unknown
- 2021-12-16 EP EP21831047.2A patent/EP4262978A1/en not_active Withdrawn
- 2021-12-16 AU AU2021403606A patent/AU2021403606B2/en active Active
- 2021-12-16 CN CN202180085151.XA patent/CN116710463A/zh active Pending
-
2023
- 2023-06-15 CL CL2023001750A patent/CL2023001750A1/es unknown
- 2023-06-18 SA SA523441263A patent/SA523441263B1/ar unknown
- 2023-06-21 CO CONC2023/0008049A patent/CO2023008049A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3202328A1 (en) | 2022-06-23 |
| IL303795A (en) | 2023-08-01 |
| JP2024502231A (ja) | 2024-01-18 |
| SA523441263B1 (ar) | 2025-01-07 |
| AU2021403606B2 (en) | 2024-11-14 |
| MX2023007244A (es) | 2023-06-29 |
| CO2023008049A2 (es) | 2023-06-30 |
| PH12023551406A1 (en) | 2024-01-22 |
| WO2022129283A1 (en) | 2022-06-23 |
| KR20230121827A (ko) | 2023-08-21 |
| AU2021403606A1 (en) | 2023-06-22 |
| CN116710463A (zh) | 2023-09-05 |
| EP4262978A1 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR132703A1 (es) | Compuestos tricíclicos y usos de los mismos | |
| ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2022017903A2 (es) | Compuestos de dihidroquinolinsulfonamida de ciclobutilo | |
| CL2025002925A1 (es) | Compuestos derivados de pirido[4,3–d]pirimidina y uso para tratar cáncer. | |
| AR008577A1 (es) | Pirazolopirimidinas, una composicion que las comprende, un procedimiento para preparar dicha composicion, un procedimiento para su preparacion,compuestos intermediarios de las mismas y un procedimiento para su preparacion | |
| CL2024003450A1 (es) | Compuestos y usos de estos | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| MA45223B1 (fr) | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| CO2022000749A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| CO2024002075A2 (es) | Compuestos n-acilhidrazónicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de estos y kits | |
| UY39681A (es) | Derivados de ciclobutilo 1,3–sustituidos y sus usos | |
| CO2023008049A2 (es) | Compuestos químicos útiles para inhibir los canales de sodio activados por voltaje de nav1.8 y tratar las enfermedades mediadas por nav1.8 | |
| AR035587A1 (es) | Un compuesto derivado de la triptamina y sus analogos, y una composicion farmaceutica que lo contiene | |
| CR20240481A (es) | DERIVADOS DE PIRROLIDINONA COMO INHIBIDORES DE QUINASA INDUCTORA DE NF-kB | |
| PY2404093A (es) | Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y kits | |
| UY40627A (es) | Compuestos arilpiridinas bloqueadores de nav 1.7 y/o nav 1.8, sus procesos de obtención... | |
| UY39882A (es) | COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS | |
| UY40629A (es) | Amidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos.... | |
| AR126389A1 (es) | Compuestos tricíclicos como inhibidores de kras | |
| CO2025011772A2 (es) | Hidroxamatos bloqueadores de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y kits | |
| CO2025000063A2 (es) | Compuestos químicos | |
| UY40625A (es) | COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN... | |
| MX2023012086A (es) | Composiciones y metodos para inhibir la expresion del miembro 3 del grupo h de la subfamilia 1 de receptores nucleares (nr1h3). |